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Abstract
Background: Molecular classification of human breast cancers has identified at least 5 distinct tumor subtypes;
luminal A, luminal B, Her2-enriched, basal-like and claudin-low. The claudin-low subtype was identified in 2007 and
is characterized by low expression of luminal differentiation markers and claudins 3, 4 and 7 and high levels of
mesenchymal markers. Claudin-low tumors have a reported prevalence of 7-14% and these tumors have a poor
prognosis.
Results: In this study we report the characterization of several cell lines established from mammary tumors that
develop in MTB-IGFIR transgenic mice. Two lines, RM11A and RJ348 present with histological features and gene
expression patterns that resemble claudin-low breast tumors. Specifically, RM11A and RJ348 cells express high
levels of the mesenchymal genes Zeb1, Zeb2, Twist1 and Twist2 and very low levels of E-cadherin and claudins 3,
4 and 7. The RM11A and RJ348 cells are also highly tumorigenic when re-introduced into the mammary fat pad of
mice.
Conclusions: Mammary tumor cells established from MTB-IGFIR transgenic mice can be used as in vitro and in
vivo model systems to further our understanding of the poorly characterized, claudin-low, breast cancer subtype.
Background
Molecular profiling has identified 5 distinct subtypes of
human breast tumors, luminal A, luminal B, HER2-
enriched, basal-like and claudin-low [1-7]. Luminal A
and luminal B tumors are estrogen receptor positive,
cytokeratin 8 and 18 positive and have a good prognosis.
Luminal B tumors have similar characteristics as luminal
A tumors but have a poorer prognosis than luminal A
tumors [1-3]. HER2-enriched tumors are characterized
by high expression of HER2 while basal-like tumors do
not express cytokeratins associated with luminal epithe-
lial cells (cytokeratins 8 and 18) but do express cytoker-
atins 5, 6 and 14 as well as vimentin [1-3]. Claudin-low
tumors express mesenchymal genes such as Twist1,
Twist2, Zeb1, Zeb2, Slug and Snail and low levels of E-
cadherin and claudins 3, 4 and 7 [6,7].
One approach to determining which subtype of
human breast cancer a particular mouse mammary
tumor or mammary tumor cell line is in fact modeling
is through the use of DNA microarrays and cluster ana-
lysis with human tumors. We utilized this approach for
the mammary tumors that arise in the MTB-IGFIR
transgenic mice. Overexpression of IGF-IR in mammary
epithelial cells in MTB-IGFIR transgenic mice leads to
the development of mammary tumors and these tumors
have been designated primary mammary tumors or
PMTs [8]. Downregulation of the IGF-IR transgene in
established mammary tumors results in the regression
of most of the tumors, however, some of the tumors
recur and do not express the IGF-IR transgene. Since
these tumors that recur take on a spindle-shape mor-
phology they have been designated recurrent spindle
tumors or RSTs [9].
Cluster analysis with human breast tumors revealed
that the PMT samples cluster most closely with 51 of
58 human basal-like tumors and a small number of
claudin-low and HER2-enriched tumors. The RSTs clus-
tered with a group of 5 claudin-low breast tumors and 1
normal sample (unpublished observation).
In this manuscript, 3 cell lines derived from MTB-
IGFIR mammary tumors have been characterized. It was
observed that two of these cell lines, RM11A and RJ348,
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Zeb1, Zeb2 and vimentin and low levels of E-cadherin
as well as claudins 3, 4 and 7 indicating that these cells
most likely resemble human claudin-low tumors. One
other cell line, RJ345 retains the expression of claudins
3, 4 and 7, E-cadherin and expresses only low levels of
vimentin. Based on this gene expression pattern, RJ345
cells most likely resemble human luminal tumors.
Importantly, the RM11A and RJ348 cells rapidly form
tumors when re-introduced into the mammary fad pads
of wild type mice thus providing an in vivo model to
complement the in vitro studies.
Materials and methods
Cell lines and culture conditions
Cell lines used for this study were derived from tumors
that developed in MTB-IGFIR transgenic mice as
described in [8]. RM11A cells were isolated from a pri-
mary mammary tumor that expressed high levels of
IGF-IR transgene and have been previously character-
ized [8,10]. RJ345 cells were isolated from an indepen-
dent MTB-IGFIR mammary tumor that expressed high
levels of IGF-IR. RJ348 cells were isolated from an IGF-
IR-independent recurrent tumor [9]. RM11A, RJ345 and
RJ348 cells were cultured in media described in [10]
with RM11A and RJ345 being cultured in media supple-
mented with 10 μg/mL doxycycline for transgene induc-
tion while RJ348 cells were cultured in doxycycline-free
media. 4T1 cells, characterized in [11] were obtained
from the ATCC (Manassas, VA) and were cultured in
DMEM media containing 10% FBS, 1 mM sodium pyru-
vate, 10 mM Hepes and 4 mM L-glutamine. MCF-7
cells were cultured in DMEM media containing 10%
FBS and 4 mM L-glutamine while MDA-MB-231 cells
were cultured in RPMI media containing 5% FBS and 4
mM L-glutamine. All cells were maintained at 37°C with
5% CO2.
Real time PCR
Total RNA was extracted from cells cultured to approxi-
mately 75% confluency, 2d after plating using the
Ambion mirVANA miRNA isolation kit (Applied Bio-
systems, Streetsville, ON), in accordance with the manu-
facturer’s instructions (without the miRNA enrichment
step). Real time PCR was performed as described in [9].
All primers were obtained from Origene (Rockville,
MD).
Animal experiments
Syngeneic mammary gland injections were performed as
described in [10]. Briefly, 1 × 10
3,1×1 0
4,o r5×1 0
5
R J 3 4 8c e l l so r5×1 0
5 or 2.5 × 10
6 RJ345 cells were
injected in each 4
th inguinal mammary gland of wild type
FVB mice. Mice were palpated twice per week. Metastasis
was assessed through serial sectioning of lung tissue with
subsequent H&E staining. Animals were housed and
cared for following the guidelines established by the Cen-
tral Animal Facility at the University of Guelph and the
Canadian Council on Animal Care.
Statistics
Statistical significance was determined using an ANOVA
followed by a Tukey’s HSD post-hoc test. Values were
considered statistically significant when p < 0.05.
Results
Previous work demonstrated that IGF-IR overexpression
in mammary epithelial cells in MTB-IGFIR transgenic
mice resulted in the development of mammary tumors
with characteristics similar to human basal breast
tumors (unpublished observations). Immunohistochem-
ical analysis revealed that these tumors contained cells
expressing a mixture of luminal and basal cytokeratins
[8]. The mammary tumors that develop following IGF-
IR downregulation have characteristics similar to human
claudin-low tumors. Immunohistochemical analysis of
these tumors revealed that these tumor cells expressed
primarily basal cytokeratins [9]. To facilitate our under-
standing of this model, 3 cell lines have been derived.
Two of cell lines (RJ345 and RM11A) were derived from
primary mammary tumor that expressed high levels of
IGF-IR while RJ348 was derived from a tumor that
recurred following IGF-IR downregulation (Table 1).
To characterize the murine mammary tumor cell lines
derived from MTB-IGFIR transgenic mice [8,11], qRT-
PCR was performed for the epithelial marker E-cadherin
and several mesenchymal genes. As a control, 4T1 cells
were included in this experiment as they have previously
been shown to express high levels of E-cadherin [12]. As
shown in Table 2, 4T1 and RJ345 cells express the
Table 1 Source of Mammary Tumor Cell Lines
Cell Line Tumor Derived From Human Breast Tumor Similarity
1
RJ345 primary mammary tumor 51/58 basal-like, 4/17 claudin-low and 2/31 HER2-enriched tumors
RM11A primary mammary tumor 51/58 basal-like, 4/17 claudin-low and 2/31 HER2-enriched tumors
RJ348 recurrent spindle tumor 5/17 human claudin-low tumors and 1/15 normal samples
1Human breast tumor similarity is based on cluster analysis of our primary mammary tumors and recurrent spindle tumors with human breast tumor samples as
described in [6].
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cells express very low levels of E-cadherin. With respect
to mesenchymal genes, RJ348 and RM11A cells
expressed higher levels of Twist1, Twist2, Zeb1, Zeb2
than the 4T1 and RJ345 cells (Table 2).
Next western blotting was used to confirm the high
level of E-cadherin protein in the 4T1 and RJ345 cells
(Figure 1). In addition, vimentin, a mesenchymal mar-
ker, was found at high levels in the RJ348 cells and
RM11A cells and at lower levels in the 4T1 and RJ345
cells. Two human breast cancer cell lines, MCF-7 which
represent human luminal tumors and MDA-MB-231
which represent human claudin-low tumors were
included as controls in the western blots. As expected,
MCF-7 cells expressed high levels of E-cadherin and
essentially no vimentin while MDA-MB-231 had the
opposite pattern of expression (Figure 1).
Since the tumors that recurred following IGF-IR
downregulation clustered with claudin-low tumors, the
expression of claudins 3, 4 and 7 were evaluated in the
murine mammary tumor cell lines. RT-PCR analysis
revealed that RJ348 and RM11A cells had considerably
lower levels of claudins 3, 4 and 7 compared to either
the 4T1 or RJ345 cells (Table 3).
The ability of 4T1 [11] and RM11A [10] cells to form
tumors when injected into the mammary fat pad of
syngeneic mice has previously been described. Since the
ability of RJ345 and RJ438 cells to form tumors follow-
ing intramammary injection had not been evaluated,
cells from these lines were injected into the mammary
fat pads of wild type, female FVB mice. The initial
round of injections utilized 5 × 10
5 cells for each of the
cell lines, RJ345 and RJ348. By 11 days post injection, all
of the mice receiving 5 × 10
5 RJ348 cells had palpable
tumors in both mammary glands (Table 4). By 20 days
post injection the tumors had reached approximately 17
mm in diameter (the maximum size allowed by the
Canadian Council of Animal Care) and mice were there-
fore euthanized. RJ345 cells failed to form tumors even
after 14 weeks (the point at which the experiment was
ended). Based on these findings, a second round of
injections were performed using either 1 × 10
3 or 1 ×
10
4 RJ348 cells or 2.5 × 10
6 RJ345 cells. Both concentra-
tions of the RJ348 injections produced tumors however
the tumor incidence declined to 33% when only 1 × 10
3
RJ348 cells were injected. One observation with the
injection of 1 × 10
3 RJ348 cells is that the tumors fre-
quently became ulcerated when tumors were only
approximately 7 mm in diameter. RJ345 cells formed
tumors when 2.5 × 10
6 cells were utilized in 50% of the
mammary glands. These tumors were not palpable 14
weeks after injection but were found during necropsy.
Histological analysis of the RJ348 mammary tumors
revealed tumors with spindle shaped morphology (Fig-
ure 2A, B). The tumors induced by the injection of
RJ345 cells produced tumors with similar histologic fea-
tures to the RJ348 injections (Figure 2C, D). Lung tissue
from tumor bearing mice was analyzed macroscopically
and microscopically for the presence of metastasis; no
such lesions were identified (data not shown).
Discussion
We have recently performed DNA microarray analysis
and hierarchal clustering of mammary tumors that
develop in MTB-IGFIR transgenic mice with other
mouse mammary tumor models and with human breast
tumors. It was observed that the mammary tumors
induced by IGF-IR overexpression clustered most closely
with murine mammary tumor models presenting with a
basal or mixed cell lineage tumors and primarily with
Table 2 Expression of Epithelial and Mesenchymal Genes
Gene 4T1 RJ345 RJ348 RM11A
E-cadherin 154 ± 28.2 75.0 ± 19.8 0.87 ± 0.15
a 1.01 ± 0.06
a
Twist1 0.29 ± 0.05 0.13 ± 0.02 0.67 ± 0.06 0.65 ± 0.23
Twist2 0.02 ± 0.01 0.13 ± 0.04 0.90 ± 0.15
a, b 0.91 ± 0.06
a, b
Zeb1 0.02 ± 0.01 0.12 ± 0.04 0.89 ± 0.22
a, b 1.50 ± 0.16
a, b
Zeb2 0.31 ± 0.09 0.02 ± 0.01 0.95 ± 0.04
a, b 1.08 ± 0.18
a, b
Data is expressed relative to HPRT. Values are displayed as mean ± SEM; n = 3
aSignificantly different (p < 0.05) than 4T1 cells
bSignificantly different (p < 0.05) than RJ345 cells.
Figure 1 Western blot of the epithelial marker E-cadherin and
the mesenchymal marker vimentin in 4T1, RJ345, RJ48,
RM11A, MCF-7 and MDA-MB-231 cells. b-actin was used as a
loading control.
Table 3 Expression of Claudin Genes
Gene 4T1 RJ345 RJ348 RM11A
Claudin-3 95.8 ± 73.8 25.2 ± 13.8 0.49 ± 0.23 0.72 ± 0.39
Claudin-4 520 ± 56.3 252 ± 74.5 0.31 ± 0.14
a,b 0.53 ± 0.26
a,b
Claudin-7 167 ± 27.7 99.5 ± 31.6 0.20 ± 0.08
a,b 0.47 ± 0.27
a,b
Data is expressed relative to HPRT. Values are displayed as mean ± SEM.
aSignificantly different (p < 0.05) than 4T1 cells
bSignificantly different (p < 0.05) than RJ345 cells.
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the MTB-IGFIR transgenic mice that recur following
IGF-IR downregulation cluster most closely with murine
mammary tumor models presenting with basal/myoe-
pithelial features and primarily with human claudin-low
tumors (unpublished observation).
To complement our transgenic approach, cell lines
have been isolated from some of the mammary tumors
that arose in the MTB-IGFIR transgenic mice. One cell
line, RM11A, has been partially characterized previously
and this cell line displayed a spindle-shaped morphology
in culture and expressed basal cytokeratins (cytokeratins
5 and 14) despite being derived from a tumor presenting
with histologic features consistent with a luminal
phenotype. These luminal appearing tumors do fre-
quently contain clusters of cells that stain positive for
basal cytokeratins and take on a more mesenchymal
phenotype [9]. This study confirms the findings of the
previous report [10] and further demonstrates that
RM11A cells express the mesenchymal protein vimentin,
a number of mesenchymal genes (Twist1, Twist2, Zeb1
and Zeb2) and little or no E-cadherin (luminal epithelial
marker). In addition, the RM11A cells expressed low
levels of claudins 3, 4 and 7 suggesting that these cells
have a gene expression pattern similar with claudin-low
tumors. Similarly, the RJ348 cells expressed a similar
gene expression profile suggesting that they to represent
claudin-low breast tumors.
Table 4 Tumor Incidence Following Injection of RJ345 or RJ348 cells
Cell
Line
Number of Cells
Injected
Number of Mammary Glands
Injected
Number of Mammary Glands with Tumors
(percentage)
Tumor Onset
(days)
RJ345 5 × 10
5 14 0 (0%) N/A
1
RJ345 2.5 × 10
6 6 3 (50%) N/A
1
RJ348 1 × 10
3 10 3 (33%) 43.6 ± 17.7
1,2
RJ348 1 × 10
4 10 10 (100%) 22.7 ± 2.0
RJ348 5 × 10
5 10 10 (100%) 11 ± 0
1Mice with non-palpable tumors were euthanized 14 weeks after tumor cell injection.
2Numbers represent mean ± SEM.
Figure 2 Hematoxylin and Eosin stained sections of tumors induced by injection of RJ348 cells (A, B) or RJ345 cells (C, D) into the
mammary fat pad of wild type mice. Panels B and D represent higher magnification images of panels A and B, respectively. Scale bars 100
μm for A and C and 50 μm for B and D.
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cells within mammary tumors induced by IGF-IR over-
expression appear luminal, these tumors share gene
expression profiles with human basal tumors. The fact
that RM11A cells possess claudin-low features also sug-
gests that some of the tumors may have small pockets
of cells containing a claudin-low genotype. These small
pockets of claudin-low cells or individual claudin-low
cells may explain why all of the small mammary tumors
and most of the large mammary tumors regress to a
non-palpable state following IGF-IR downregulation [9].
Since claudin-low tumors possess features of stem cells
[7], it is possible that the tumors that regress and recur
or only partially regress are those that contain claudin-
low cells. If RJ348 cells are enriched with stem cell char-
acteristics, this would explain why as few as 1000
injected cells are capable if initiating mammary tumor
development (similar limiting dilution studies have not
been performed in RM11A cells).
Claudin-low tumors were first identified by Hersch-
kowitz et al [6] as a distinct molecular subtype of
human breast cancer. These tumors have a prevalence
of approximately 7-14% and a have a poor prognosis
compared to luminal A tumors [7]. Although a num-
ber of human tumor cell lines have been identified as
sharing features of claudin-low tumors (MDA-MB-
435, MDA-MB-436, Hs578T, BT549, MDA-MB-231,
MDA-MB-157, SUM1315MO2, SUM159PT and
HBL100), fewer claudin-low, murine mammary tumor
cell lines have been established [7]. Since the RM11A
and RJ348 cells form tumors when re-injected into the
mammary fat pat, these cells provide us with a system
where claudin-low tumors can be evaluated in vitro
and in vivo in immunocompetent mice. The immune
status of mice may be particularly important when
studying claudin-low tumors as one of the hallmarks
of this tumor type is an increase in immune-related
genes [7].
RJ345 cells express the epithelial marker E-cadherin
and little or no mesenchymal markers suggesting that
these cells represent luminal or basal epithelial cells.
The fact that RJ345 cells form mammary tumors only
after the injection of 2.5 × 10
6 cells suggest that this cell
line is weekly tumorigenic and this may be due to the
small number of cells with stem cell characteristics.
Since these cells are only weakly tumorigenic, they will
be useful in identifying genes that facilitate tumorigen-
esis through gene alteration and subsequent mammary
transplantation. The RJ345 cells will be useful in identi-
fying genes that facilitate tumor initiation and growth.
Therefore, we have created a model system where
tumor cells with claudin-low characteristics can be eval-
uated in vitro and in vivo. This system should improve
our understanding of human claudin-low breast tumors
and possible therapeutic strategies to treat these tumors
which typically have a poor prognosis.
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